The NYSE Amex listed penny stock of Inovio Pharmaceuticals, Inc. (INO) exploded today after reporting positive test results on their next-generation HIV vaccine, a 7X increase (7% to 52%). Shares of INO stock set a new 52 week high, 1.57, within minutes of the opening bell before pulling back. With both INO stock and another biotech which Avtar S. Dhillon is deeply involved with, Arch Therapeutics, Inc. (ARTH), also setting a new 52 week high today, the theory that success breeds success is a perfect fit for today’s performance.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
INO Stock Quote
Market Cap: 257.31M
Last: 1.45 ▲ +0.27 (+22.88%)
Issued and Outstanding: 179,940,861
1st Resistance Point: 1.5587
2nd Resistance Point: 1.6893
1st Support Level: 1.3087
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
For those unfamiliar with Inovio Pharmaceuticals, the Company’s DNA-based SynCon® technology was designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. Inovio’s long list of vaccines which are in preclinical development and existing clinical programs include:
- cervical dysplasia/cancer (therapeutic);
- influenza (preventive);
- prostate cancer (therapeutic);
- leukemia (therapeutic);
- hepatitis C virus;
- hepatitis B virus;
- HIV; and
The list of partners and collaborators Inovio has in their vaccine programs reads like list of “Top Gun” medical institutions, drug makers and government agencies:
- University of Pennsylvania;
- Drexel University;
- National Microbiology Laboratory of the Public Health Agency of Canada;
- Program for Appropriate Technology in Health/Malaria Vaccine Initiative;
- National Institute of Allergy and Infectious Diseases;
- Merck (NYSE: MRK);
- University of Southampton;
- United States Military HIV Research Program;
- U.S. Army Medical Research Institute of Infectious Diseases;
- HIV Vaccines Trial Network; and
- United States Department of Homeland Security
The news today annocuning the peer-reviewed publication of results from two phase I trials (HVTN 070 and HVTN 080) of Inovio Pharmaceuticals’ PENNVAX®-B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without Inovio’s proprietary CELLECTRA® electroporation delivery device follows up prior excellent news. On Monday, the Company announced that, in a preclinical study of its influenza DNA vaccine against the virulent, newly emergent H7N9 flu virus, 100% of the vaccinated animals were protected against sickness and death when they were challenged with a lethal dose of H7N9 virus.
As for INO stock itself, today’s high of 1.57 is the highest level the shares have traded since January, 2011 when INO stock hit 1.56. However, by leaps and bounds, today’s volume is the highest ever in over 3 years and for good reason.
INO stock, at today’s HOD has gained 220% since bottoming out from its previous bull run of 100% to start the year. With Dhillon’s success rate in putting up the numbers for investors in penny stocks which he is directly involved with, could ARTH stock be on the same path as INO in respect of gains since the 0.79 alerts we issued?
About INO Stock
Inovio Pharmaceuticals, Inc. is engaged in the discovery and development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases.
Click here to view the SEC filings for INO.
Click here to view the website for Inovio Pharmaceuticals.
Last 5 Trading Sessions:
Stay Connected With Us:
INO shattered all of its previous records today and is a swing traders dream at present. With resistance levels tough to surpass from this point and support hanging tough at the 1.30 level, a pull back is imminent and very much worthy of an addition to the list of penny stocks to watch. On a side note, ARTH has performed very well this week since being picked up by Paragon and should continue to see its PPS stay above the 1.20 level before it also breaks out.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share